Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

MedPage Today) — Liposomal daunorubicin and cytarabine (Vyxeos) didn’t hold up to standard daunorubicin/cytarabine induction therapy in children and young adults with newly diagnosed acute myeloid leukemia (AML), a phase III trial from the Children…
Read More